Alendronate/interleukin-1β cotreatment increases interleukin-6 in bone and UMR-106 cells: Dose dependence and relationship to the antiresorptive effect of alendronate

Journal of Bone and Mineral Research

Volumn 13, Issue 5, 1998, Pages 786-792

  Sanders, Jennifer L ^a   Tarjan, Gabor ^a   Foster, Shirley A ^a   Stern, Paula H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 1; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE; BONE MASS; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; FETUS; METABOLIC BONE DISEASE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; RAT; TISSUE CULTURE; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; ORGAN CULTURE TECHNIQUE; PATHOLOGY;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE RESORPTION; CELL LINE; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOMETHACIN; INTERLEUKIN-1; INTERLEUKIN-6; ORGAN CULTURE TECHNIQUES; OSTEOBLASTS; RATS;

EID: 0031595156     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.5.786     Document Type: Article

References (46)

1. Ruml LA, Dubois SK, Roberts ML, Pak CY 1995 Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res 10:655-662.
2. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E 1991 Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-247.
3. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC II 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
4. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ 1995 Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390.
5. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443.
6. Adami S, Salvagno G, Guarrera G, Montesanti F, Garavelli S, Rosini S, Lo Cascio V 1986 Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int 39:226-229.
7. Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ 1996 Biochemical and radiologie improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101:341-348.
8. Adami S, Bolzicco GP, Rizzo A, Salvagno G, Bertoldo F, Rossini M, Suppi R, Lo Cascio V 1987 The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner 2:395-404.
9. Rizzoli R, Buchs B, Bonjour JP 1992 Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate, Int J Cancer 50:706-712.
10. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ 1993 Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 11:1618-1623.
11. Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E 1987 Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis: Comparison with dichloromethylene diphosphonate. Arch Intern Med 147:1629-1633.
12. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA 1989 Antiresorptive dose-response relationships across three generations of biphosphonates. Drugs Exp Clin Res 15:389-396.
13. Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP 1980 APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23: 1193-1204.
14. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331.
15. Heinrich PC, Castell JV, Andus T 1990 Interleukin-6 and the acute phase response. Biochem J 265:621-636.
16. Schweitzer DH, van Oostendorp-de Ruit M, van der Pluijm G, Löwik CW, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethyl-aminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962.
17. Aarden LA, de Groot ER, Schaap OL, Lansdorp PM 1987 Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411-1416.
18. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, Kishimoto T, Suda T 1990 IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297-3303.
19. Löwik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, Papapoulos SE 1989 Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162: 1546-1552.
20. van Damme J, Cayphas S, Opdenakker G, Billiau A, van Snick J 1987 Interleukin 1 and poly(rI)-poly(rC) induce production of a hybridoma growth factor by human fibroblasts. Eur J Immunol 17:1-7.
21. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD 1990 IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144:4226-4230.
22. Black K, Garrett IR, Mundy GR 1991 Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128:2657-2659.
23. Stern PH, Phillips TE, Mavreas T 1980 Bioassay of 1,25-dihydroxyvitamin D in human plasma purified by partition, alkaline extraction, and high-pressure chromatography. Anal Biochem 102:22-30.
24. McGee DW, Beagley KW, Aicher WK, McGhee JR 1992 Transforming growth factor-β enhances interleukin-6 secretion by intestinal epithelial cells. Immunology 77:7-12.
25. Hansen MB, Nielsen SE, Berg K 1989 Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Meth 119:203-210.
26. Tarjan G, Stern PH 1995 Triiodothyronine potentiates the stimulatory effects of interleukin-1β on bone resorption and medium interleukin-6 content in fetal rat limb bone cultures. J Bone Miner Res 10:1321-1326.
27. Sato K, Fujii Y, Kasono K, Saji M, Tsushima T, Shizume K 1986 Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun 138:618-624.
28. Hoffmann O, Klaushofer K, Gleispach H, Leis HJ, Luger T, Koller K, Peterlik M 1987 Gamma interferon inhibits basal and interleukin 1-induced prostaglandin production and bone resorption in neonatal mouse calvaria. Biochem Biophys Res Commun 143:38-43.
29. Klein-Nulend J, Pilbeam CC, Harrison JR, Fall PM, Raisz LG 1991 Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-1, and Cortisol in cultured mouse parietal bones. Endocrinology 128:2503-2510.
30. Tran JM, Kleeman CR, Green J 1995 Production of interleukin-6 by osteoblastic cells is independent of medium inorganic phosphate. Biochem Mol Med 55:90-95.
31. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
32. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T 1995 A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17:137-144.
33. Zimolo Z, Wesolowski G, Rodan GA 1995 Acid extrusion is induced by osteoclast attachment to bone: Inhibition by alendronate and calcitonin. J Clin Invest 96:2277-2283.
34. Nishikawa M, Akatsu T, Katayama Y, Yasutomo T, Kado S, Kugai N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9-14.
35. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA 1996 Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 93:3068-3073.
36. Vitté C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333.
37. van der Pluijm G, Löwik CW, de Groot H, Alblas MJ, van der Wee-Pals LJ, Bijvoet OL, Papapoulos SE 1991 Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone expiants. J Bone Miner Res 11:1203-1210.
38. Bellido T, Borba VZ, Roberson P, Manolagas SC 1997 Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathways by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138:3666-3676.
39. Hughes FJ, Howells GL 1993 Interleukin-6 inhibits bone formation in vitro. Bone Miner 21:21-28.
40. Franchimont N, Durant D, Canalis E 1997 Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures. Endocrinology 138:3380-3386.
41. Passeri G, Girasole G, Ulietti V, Giuliani N, Pedrazzoni M, Sartori L, Jilka RL, Manolagas SC 1994 Bisphosphonates inhibit IL-6 production by human osteoblastic cells MG-63. J Bone Miner Res 9 (Suppl 1):S320 (abstract B2).
42. Van Damme J, Cayphas S, Van Snick J, Conings R, Put W, Lenaerts JP, Simpson RJ, Billiau A 1987 Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). Eur J Biochem 168:543-550.
43. Meyer TA, Wang J, Tiao GM, Ogle CK, Fischer JE, Hasselgren PO 1995 Sepsis and endotoxemia stimulate intestinal interleukin-6 production. Surgery 118:336-342.
44. Lacki JK, Klama K, Mackiewicz SH, Mackiewicz U, Müller W 1995 Circulating interluekin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: Preliminary report. Inflamm Res 44:24-26.
45. De Simoni MG, Sironi M, De Luigi A, Manfridi A, Montovani A, Ghezzi P 1990 Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J Exp Med 171:1773-1778.
46. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphophonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.